Syndax Pharmaceuticals
SNDX
130 hedge funds and large institutions have $1.08B invested in Syndax Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 55 increasing their positions, 43 reducing their positions, and 25 closing their positions.
45% more call options, than puts
Call options by funds: $5.55M | Put options by funds: $3.82M
28% more capital inflows, than outflows
Capital inflows: $207M | Capital outflows: $162M
28% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 43
0.07% more ownership
Funds ownership: 100.43% → 100.5% (+0.07%)
8% less funds holding
Funds holding: 142 → 130 (-12)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
48% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avoro Capital Advisors
New York
|
+$46.3M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$33.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$21.5M |
| 4 |
CC
Casdin Capital
New York
|
+$12.4M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$26M |
| 2 |
Millennium Management
New York
|
-$16.8M |
| 3 |
BVF Inc
San Francisco,
California
|
-$16.2M |
| 4 |
VA
VR Adviser
New York
|
-$11.8M |
| 5 |
Two Sigma Investments
New York
|
-$7.99M |
SNDX Hedge Fund Activity: Q1 2021 in Review
130 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2021, worth a combined $1.08B — up 4.7% from $1.03B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of SNDX and 13 opened new positions — a net loss of 12 holders — while 43 trimmed existing stakes and 55 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $46.3M. The largest seller was OrbiMed, exiting entirely with an estimated $26M sold.
- 130 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2021, down from 142 in Q4 2020.
- Funds reported $1.08B of Syndax Pharmaceuticals stock for Q1 2021, up 4.7% quarter-over-quarter.
- 13 funds opened new Syndax Pharmaceuticals positions in Q1 2021 and 25 closed out, a net change of -12 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2021 was Avoro Capital Advisors, an estimated $46.3M added.
- The largest Syndax Pharmaceuticals seller in Q1 2021 was OrbiMed, an estimated $26M sold.
Based on aggregated 13F filings for Q1 2021.